Compass Therapeutics Gets Nasdaq Deficiency Notice After FDA Survival Trial Demand
Company Background
Compass Therapeutics is a clinical-stage oncology biopharmaceutical company based in Boston that develops antibody-based cancer therapies. It has no approved products and no product revenue. Its lead asset, tovecimig, is a bispecific antibody targeting DLL4 and VEGF-A designed to disrupt tumor angiogenesis in solid tumors. The company raised $129 million in a 2025 public offering, ending that year with $209 million in cash and marketable securities.
Compass entered 2026 on strong footing. Its pivotal Phase 2/3 COMPANION-002 trial in second-line biliary tract cancer met its primary overall response rate endpoint and a key secondary progression-free survival endpoint: ORR was 18.0% for the tovecimig-plus-paclitaxel combination versus 5.3% for paclitaxel alone (p=0.0228), and median PFS was 4.7 versus 2.6 months (HR=0.44, p<0.0001). Management was targeting a BLA filing before year-end 2026 and a potential 2027 approval, and had begun incurring pre-commercialization expenses in anticipation.
That timeline collapsed on September 22, 2026, when the FDA recommended Compass conduct an additional trial demonstrating a survival benefit before proceeding with a BLA submission. The overall survival analysis in COMPANION-002 had not met statistical significance, confounded by a 54% crossover rate from the control arm — patients initially randomized to paclitaxel alone who subsequently received tovecimig and lived substantially longer than those who did not cross over. Compass publicly disputed the FDA's position, stating it does not believe a new trial is warranted based on COMPANION-002's data and the unmet need in biliary tract cancer, and said it would continue BLA preparations while engaging the agency further.
What Was Disclosed
Compass received a deficiency letter from Nasdaq's Listing Qualifications Department on November 19, 2026, notifying the company that its common stock has closed below the minimum $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The letter has no immediate effect on the listing — shares continue to trade on the Nasdaq Capital Market under the ticker CMPX — but it starts a formal compliance clock.